Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02088541 · ClinicalTrials.gov registry record · Phase 2
Selinexor (KPT-330) in Older Patients With Relapsed AML
A Phase 2 study, sponsored by Karyopharm Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 317
- Enrollment target
NCT02088541 is a Phase 2 study that has completed, run by Karyopharm Therapeutics. The registered enrollment target is 317 participants.
The verdict
NCT02088541, a Phase 2 study, has completed, sponsored by Karyopharm Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 317 participants
- Enrollment target
Study Summary
This is a randomized, multicenter, open-label, phase 2 study of the SINE compound, selinexor given orally versus specified investigator choices (one of three potential salvage therapies). Participants age ≥ 60 years with relapsed or refractory AML of any type except for AML M3, after one prior therapy only, who have never undergone and who are not currently eligible for stem cell transplantation and are currently deemed unfit for intensive chemotherapy.
Interventions
- DRUG Hydroxyurea
- DRUG Selinexor
- DRUG Ara-C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2014-03 |
| Est. Completion | 2018-01-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02088541
The ClinicalTrials.gov registry entry for NCT02088541 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 317 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Karyopharm Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Hydroxyurea is the first listed.
NCT02088541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02088541 about?
NCT02088541 is a clinical study titled "Selinexor (KPT-330) in Older Patients With Relapsed AML". This is a randomized, multicenter, open-label, phase 2 study of the SINE compound, selinexor given orally versus specified investigator choices (one of three potential salvage therapies). Participants age ≥ 60 years with relapsed or refractory AML of any type except for AML M3, after one prior thera...
What is the current status of trial NCT02088541?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 317 participants. The study started on 2014-03. Estimated completion is 2018-01-08.
What interventions are being tested in trial NCT02088541?
The interventions under investigation include: Hydroxyurea (DRUG), Selinexor (DRUG), Ara-C (DRUG).
Who is sponsoring clinical trial NCT02088541?
This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.